Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu
Rani Therapeutics
US$73m

Canaccord Genuity Acted as a Joint Bookrunner in an Initial Public Offering for Rani Therapeutics

Transaction Overview:

Rani Therapeutics Holdings, Inc. (the “Company”) (Nasdaq:RANI), priced its $73.3 million initial public offering on July 30, 2021 at a price of $11.00 per share. The Company issued 6,666,667 shares of common stock. In addition, Rani Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 common shares at the initial public offering price, less underwriting discounts and commissions.

Company Overview:

Rani Therapeutics is a clinical stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics. Rani has developed the RaniPill capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection of biologics with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill™ capsule.

Lead Transaction Banker

More like this

 InfraVia Capital Partners
October 2021

InfraVia Capital Partners

Exclusive Financial Adviser
View transaction detail
PharmaCann
October 2021

PharmaCann

Financial Advisor (Buy-side)
View transaction detail
Vicarious Surgical Inc.
US$872m
September 2021

Vicarious Surgical Inc.

Financial/Capital Markets Advisor
View transaction detail